{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T08:34:33Z","timestamp":1719218073187},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.gastrohep.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T01:51:34Z","timestamp":1440813094000},"page":"575-582","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Coste-efectividad y seguridad de telaprevir y boceprevir para el tratamiento de la hepatitis C cr\u00f3nica en la pr\u00e1ctica cl\u00ednica"],"prefix":"10.1016","volume":"38","author":[{"given":"\u00c1lvaro","family":"Gim\u00e9nez-Manzorro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xandra","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Guadalupe","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Ochoa-Palominos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Clemente-Ricote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2015.07.002_bib0145","first-page":"107","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0150","doi-asserted-by":"crossref","unstructured":"Rantala M, van de Laar M. Surveillance and epidemiology of hepatitis B and C in Europe, a review. Eur Surveill [Internet] 2008;13(21) [consultado 25 Jun 2014]. Disponible en: http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=18880","DOI":"10.2807\/ese.13.21.18880-en"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatol Baltim Md."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0160","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32833c11a5","article-title":"Acute hepatitis C in HIV-infected men who have sex with men: An emerging sexually transmitted infection","volume":"24","author":"Van de Laar","year":"2010","journal-title":"AIDS Lond Engl."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","article-title":"The changing epidemiology of hepatitis C virus infection in Europe","volume":"48","author":"Esteban","year":"2008","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2010.03.015","article-title":"The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression","volume":"53","author":"John-Baptiste","year":"2010","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0175","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"European Association for Study of Liver EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0180","unstructured":"Ficha t\u00e9cnica Victrelis\u00ae [Internet]. European Medicines Agency; 2011 [consultado 25 Jun 2014]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002332\/WC500109786.pdf"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0185","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0190","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0195","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0200","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0205","unstructured":"Tratamiento de la hepatitis cr\u00f3nica C (VHC). 1. Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis cr\u00f3nica C (VHC) en pacientes monoinfectados. 2. Estrategia terap\u00e9utica recomendada para el uso de inhibidores de la proteasa para el tratamiento de la hepatitis cr\u00f3nica C (VHC) en pacientes monoinfectados en el \u00e1mbito del Sistema Nacional de Salud [Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2012 [consultado 25 Jun 2014]. Disponible en: https:\/\/www.msssi.gob.es\/profesionales\/farmacia\/pdf\/TRATAMIENTO_HEPATITIS_CRONICA_C.pdf"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0210","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0215","unstructured":"Ubago P\u00e9rez R, Catillo Mu\u00f1oz MA, Navarro Caballero JA, M\u00e1rquez Pel\u00e1ez S. Inhibidores de la proteasa (boceprevir y telaprevir) en el tratamiento de pacientes monoinfectados por el VHC: eficacia, seguridad y eficiencia comparada. Informe 1\/2012 [Internet]. Sevilla: Agencia de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias; 2012 [consultado 25 Jun 2014]. Disponible en: www.juntadeandalucia.es\/salud\/orgdep\/AETSA"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2013.05.019","article-title":"Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis","volume":"59","author":"Camm\u00e0","year":"2013","journal-title":"C J Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.gastrohep.2014.01.002","article-title":"Perspectivas futuras del tratamiento de la hepatitis C \u00bfsin interfer\u00f3n y ribavirina?","volume":"37","author":"Lens","year":"2014","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.27151","article-title":"Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals","volume":"60","author":"Hagan","year":"2014","journal-title":"Hepatology."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0235","unstructured":"Gonz\u00e1lez Rivas L, Morillo Verdugo R. Boceprevir y telaprevir en pacientes monoinfectados por el virus de la hepatitis C. Informe para la Gu\u00eda Farmacoterap\u00e9utica de Hospitales de Andaluc\u00eda [Internet]. Sevilla-Huelva: Comit\u00e9 de Actualizaci\u00f3n de la Gu\u00eda Farmacoterap\u00e9utica de Hospitales de Andaluc\u00eda; 2011 [consultado 25 Jun 2014]. Disponible en: http:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Enlaces\/InformesHosp_abc.htm#B"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0240","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40273-013-0080-3","article-title":"Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-na\u00efve hepatitis C patients","volume":"31","author":"Bl\u00e1zquez-P\u00e9rez","year":"2013","journal-title":"PharmacoEconomics."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0245","first-page":"418","article-title":"An\u00e1lisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente","volume":"38","author":"Buti","year":"2014","journal-title":"Farm Hosp."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0250","unstructured":"Turnes J. Coste-efectividad de los antivirales de acci\u00f3n directa. Jornadas de oto\u00f1o de la Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado. Sevilla: Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado; 2014 [consultado 20 Feb 2015]. Disponible en: http:\/\/www.javierpazo.com\/articulos\/aeeh\/20.swf"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12546","article-title":"Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort","volume":"39","author":"Backus","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0260","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experience patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"H\u00e9zode","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0265","first-page":"44","article-title":"Seguridad de boceprevir y telaprevir en la pr\u00e1ctica cl\u00ednica habitual","volume":"38","author":"L\u00f3pez-Sep\u00falveda","year":"2014","journal-title":"Farm Hosp."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0270","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/cirrhosis","volume":"58","author":"Bruno","year":"2013","journal-title":"J Hepatol."},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0275","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.07.051","article-title":"Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection \u2013a randomized trial","volume":"145","author":"Poordad","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2015.07.002_bib0280","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jhep.2013.07.014","article-title":"Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations","volume":"59","author":"Romero-G\u00f3mez","year":"2013","journal-title":"J Hepatol."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570515001685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570515001685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:04:14Z","timestamp":1567123454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570515001685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0210570515001685"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.07.002","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coste-efectividad y seguridad de telaprevir y boceprevir para el tratamiento de la hepatitis C cr\u00f3nica en la pr\u00e1ctica cl\u00ednica","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}